Table 5. Preliminary results of few agents.

Drug	Patients treated	Disease control ratea	Major treatment-related toxicities	Reference
MK0752	103	1 CR in anaplastic astrocytoma, 15 SDs in mostly GBM	GI disorders, fatigue, AST increase, rash	Krop et al., 2012 (38)
RO4929097	110	1 PR in colorectal adenocarcinoma with neuroendocrine features, 26 SDs in sarcoma, melanoma or ovarian cancer	GI events, fatigue, hypophosphatemia, rash	Tolcher et al., 2012 (58)
PF03084014	41	1 CR in papillary thyroid cancer, 4 PRs in desmoid tumors	Diarrhea, nausea, rash and fatigue	Messersmith et al., 2012 (59)
OMP-59R5	39	SDs in adenoid cystic-adenocarcinoma, sarcomas, rectal cancer, or triple-negative breast cancer	Diarrhea	Smith et al., 2012 (60)
REGN421	53	2 PRs in NSCLC and ovarian cancer, 16 SDs	Fatigue, headache, hypertension, nausea	Jimeno et al., 2013 (56)

^a, disease control rate includes complete and partial responses, and stable disease. CR, complete response; SD, stable disease; PR, partial response; GBM, glioblastoma multiforme; AST, aspartate aminotransferase; GI, gastro intestinal; NSCLC, non-small cell lung cancer.